Visa Live Takes Flight with Benson Boone at the Rocket Garden
22.10.2025 17:30:00 CEST | Business Wire | Press Release
Prepare for lift-off this November as Visa presents another unforgettable cultural moment with Visa Live at the Rocket Gardenfeaturing global chart-topping sensation, Benson Boone on November 29.
After the global success of Visa Live at le Louvre, the next chapter of the series lands at one of the world’s most iconic locations, the Rocket Garden at Kennedy Space Center Visitor Complex in Merritt Island, Florida. Headlined by Benson Boone, with a special guest to be announced, this event will be livestreamed on TikTok, inviting fans everywhere to join a night of music under the stars in a setting typically reserved for daylight exploration.
“The Visa Live experience speaks to a fundamental truth in music: the space or environment in which the music is performed actually matters to both the artist and the audience,” said Frank Cooper III, Chief Marketing Officer, Visa. “We believe that Visa Live at the Rocket Garden embodies the history of real space travel and the promise of future exploration, providing a setting for Benson Boone to deliver a never-been-seen-before experience. It reflects our commitment to reimagining the fan experience and creating new spaces for artists to create.”
Set against the awe-inspiring backdrop of the Rocket Garden at night, the event promises an atmosphere unlike anything fans or artists have experienced before. Towering rockets from the Mercury, Gemini, and Apollo eras are dramatically lit beneath the stars, creating a stunning and unforgettable landscape.
“Visa and NASA have truly gone above and beyond bringing this show together,” said Benson Boone. “This show is going to be so insanely sick and one I'll remember forever. I hope everyone likes my outfit as much as I do…”
Onsite Experiences
Visa Live at the Rocket Garden brings fans even closer to the action, pushing the boundaries for how brands, creators and technology connect global audiences to cultural moments:
- Florida residents can enter for a chance to win free tickets to this exclusive nighttime event, experiencing the Rocket Garden like never before. Florida residents ages 18+ can visit this site beginning at 9am EST on November 6 to register and enter for a chance to win1.
- CashApp Visa cardholders will receive a special cash back discount on all concert merchandise and concession purchases during the event.
Experience Visa Live on TikTok
Fans around the world can join Visa Live at the Rocket Garden via an exclusive TikTok livestream, sharing in this one-of-a-kind musical experience. The event will harness TikTok’s real-time interactivity, inviting viewers to comment, share and participate alongside those in Merritt Island - pushing the future of live music into new territory and connecting global audiences.
FAQ
Q: What is Visa Live?
Visa Live is a global music experience series from Visa, designed to unite fans and artists in iconic locations through unforgettable, often livestreamed, performances. The series puts audiences at the center of cultural moments, forging connections through music in unique settings.
Q: Where and when is this event taking place?
This Visa Live event happens at night in the Rocket Garden at Kennedy Space Center Visitor Complex - usually closed to the public after dark - November 29, 2025, making it an exceptionally exclusive experience.
Q: Who can attend the concert in person?
Tickets are not on sale to the general public, but eligible Florida residents can register to enter and have a chance to win free tickets to attend the show live in Merritt Island, while fans worldwide (and those in Florida who do not win the ticket sweepstakes) can join via a TikTok livestream.
Q: What are the benefits for CashApp Visa cardholders?
CashApp Visa Card holders will receive a special cash back discount on all concert merchandise and concession purchases during the event.
Q: Why the Rocket Garden? What makes it a unique concert venue?
The Rocket Garden features nine authentic, towering rockets from NASA's Mercury, Gemini, and Apollo programs. At night, their silhouettes shine under the stars, providing an awe-inspiring backdrop that celebrates the adventurous spirit of space exploration.
About Visa
Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
| ______________________________ |
| 1 No purchase necessary. Open only to legal U.S. residents of Florida, 18+. Ends at 11:59 pm ET on 11/20/25. Void outside Florida and where prohibited |
View source version on businesswire.com: https://www.businesswire.com/news/home/20251022480657/en/
Contacts
Media Contact
Jackie Dresch - jdresch@visa.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom